Penn Medicine Abramson Cancer Center


 

ASH 2019 Updates on MDS Treatment: Luspatercept Reduces Anemia, Lenalidomide and Epoetin Alfa Leads to Durable Responses, Experience with HMAs, ASTX727 as Alternative to IV Decitabine

83 views
February 24, 2020
Comments 0
Login to view comments. Click here to Login